By Stephen Nakrosis
Shares of Pulmatrix hit a 52-week high on the Nasdaq, more than doubling their opening price before giving back gains, following news of a planned merger with privately held biopharmaceutical company Cullgen.
In Thursday afternoon trading, the stock was up 28% at $4.58. Shares opened at $3.88, and rose to a 52-week high of $7.87 earlier in the session.
Trading in the company's shares was halted several times on Thursday, due to volatility. Trading volume was above 14 million shares shortly after 2 p.m. EST, above the stock's 65-day average volume of 67,239 shares.
The company has a public float of 3.65 million shares.
On Wednesday, Pulmatrix announced a deal to merge with Cullgen. The deal would see the combined company list of the Nasdaq under the name Cullgen Inc. The deal also calls for Pulmatrix to divest assets, including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE technology, the companies said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 14, 2024 14:24 ET (19:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。